Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
injection
|
| gptkbp:age_group |
12 months to 12 years
|
| gptkbp:approves |
gptkb:2005
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
pediatric vaccination
|
| gptkbp:combination_vaccine |
yes
|
| gptkbp:contraindication |
pregnancy
immunocompromised individuals severe allergic reaction to components |
| gptkbp:dosage_form |
gptkb:liquid
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pro Quad
|
| gptkbp:ingredients |
gptkb:mumps_virus
gptkb:rubella_virus measles virus varicella virus |
| gptkbp:is_vulnerable_to |
high
varies by region subcutaneous 2 to 8 degrees Celsius live attenuated ongoing studies for long-term effects single-dose vial available through healthcare providers demonstrated in clinical trials MMR and varicella combined VAERS reporting system consult healthcare provider for details observe for 15 minutes post-administration part of routine childhood immunizations recommended in many countries reduces incidence of diseases |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:market |
ongoing
|
| gptkbp:performance |
two doses recommended
|
| gptkbp:provides_guidance_on |
CDC recommendations
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fever
seizures rash injection site reactions anaphylaxis thrombocytopenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:trade |
gptkb:Pro_Quad
|
| gptkbp:used_for |
prevention of measles
prevention of mumps prevention of rubella prevention of varicella |
| gptkbp:vaccine_documentation |
record in immunization registry
|
| gptkbp:vaccine_expiration |
after reconstitution, use within 30 minutes
|
| gptkbp:vaccine_interactions |
immunosuppressive therapies
|
| gptkbp:vaccine_preparation |
requires reconstitution
|
| gptkbp:bfsParent |
gptkb:Merck_Vaccines
|
| gptkbp:bfsLayer |
6
|